WongPartnership acted for Biofourmis in their Series C funding round
08 Sep 2020WongPartnership acted for Boston-based Biofourmis in their Series C funding round led by Softbank Vision Fund 2 which has raised US$100 million (S$136 million). This brings the software start-up to near-unicorn status in a matter of months.
Biofourmis, which was founded in Singapore but relocated its headquarters to Boston, utilises artificial intelligence (AI) software to monitor and analyse patients’ symptoms through wearable medical devices.
The company has now raised a total of US$145 million, which includes US$35 million from its Series B round and US$10 million from its Series A round and angel investments.
Our Joint Head of the WPGrow: Start-Up / Venture Capital Practice Kyle Lee and Associate Jolynn Lim acted for Biofourmis in this transaction.